skip to Main Content

Overview

Symbol
ALIM

Price Delayed by 20 minutes

Alimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.

IR Nav

Tear Sheet IR Contacts Subscribe to News Alerts RSS Feed

Company Profile

6120 Windward Parkway, Suite 290
Alpharetta, GA 30005

1 (844) 445-8843

(678) 990 5744

info@alimerasciences.com

Recent News & Filings

Alimera Sciences New Day Trial Initiation Presentation Alimera Sciences New Day Study Webcast Corporate Presentation Quarterly Report

Investor Relations

John Marco, CORE IR
377 Oak Street
Garden City, NY 11530
Phone: 516-222-2560
E-mail: johnm@coreir.com
www.coreir.com

Transfer Agent

AST Financial, Bryan Anderson,
Relationship Manager
banderson@astfinancial.com

Auditors

Grant Thornton LLP
Joseph Heatherly, Partner,
Joseph.Heatherly@us.gt.com

Corporate Counsel

Charles Vaughn,
Nelson Mullins
(404) 322-6189
charles.vaughn@nelsonmullins.com

Click here to subscribe to IR news and filing alerts

You can opt out at any time. We do not share or sell your info.

Back To Top
Skip to content